HTG Molecular Diagnostics Past Earnings Performance
Past criteria checks 0/6
HTG Molecular Diagnostics's earnings have been declining at an average annual rate of -1.8%, while the Healthcare Services industry saw earnings growing at 17.5% annually. Revenues have been declining at an average rate of 18.1% per year.
Key information
-1.8%
Earnings growth rate
52.4%
EPS growth rate
| Healthcare Services Industry Growth | 7.9% |
| Revenue growth rate | -18.1% |
| Return on equity | -1,828.3% |
| Net Margin | -324.7% |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How HTG Molecular Diagnostics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 7 | -22 | 18 | 0 |
| 30 Jun 22 | 8 | -22 | 19 | 0 |
| 31 Mar 22 | 9 | -19 | 18 | 0 |
| 31 Dec 21 | 9 | -17 | 17 | 0 |
| 30 Sep 21 | 9 | -16 | 17 | 0 |
| 30 Jun 21 | 8 | -17 | 17 | 0 |
| 31 Mar 21 | 8 | -20 | 17 | 0 |
| 31 Dec 20 | 9 | -21 | 18 | 0 |
| 30 Sep 20 | 11 | -21 | 19 | 0 |
| 30 Jun 20 | 14 | -20 | 18 | 0 |
| 31 Mar 20 | 18 | -19 | 19 | 0 |
| 31 Dec 19 | 19 | -19 | 19 | 0 |
| 30 Sep 19 | 22 | -17 | 19 | 0 |
| 30 Jun 19 | 21 | -17 | 19 | 0 |
| 31 Mar 19 | 21 | -16 | 19 | 0 |
| 31 Dec 18 | 22 | -16 | 20 | 0 |
| 30 Sep 18 | 22 | -16 | 20 | -6 |
| 30 Jun 18 | 21 | -17 | 19 | -3 |
| 31 Mar 18 | 18 | -19 | 19 | -1 |
| 31 Dec 17 | 15 | -19 | 18 | 0 |
| 30 Sep 17 | 8 | -23 | 17 | 8 |
| 30 Jun 17 | 6 | -24 | 17 | 6 |
| 31 Mar 17 | 6 | -25 | 17 | 7 |
| 31 Dec 16 | 5 | -26 | 17 | 8 |
| 30 Sep 16 | 5 | -26 | 17 | 8 |
| 30 Jun 16 | 5 | -25 | 17 | 8 |
| 31 Mar 16 | 4 | -25 | 16 | 6 |
Quality Earnings: 65H is currently unprofitable.
Growing Profit Margin: 65H is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 65H is unprofitable, and losses have increased over the past 5 years at a rate of 1.8% per year.
Accelerating Growth: Unable to compare 65H's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 65H is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (11.6%).
Return on Equity
High ROE: 65H has a negative Return on Equity (-1828.34%), as it is currently unprofitable.